Marken has increased presence and capability in Singapore.
As part of Marken’s continued expansion of services in the APAC region, they have relocated and expanded their Singapore office to further support clients’ needs for specialty logistics services. This expansion incorporates a new directly owned, purpose-built Singapore depot to support growing customer demand for Investigational Medical Product distribution.
The new GMP compliant facility enables clients to leverage Marken’s global expertise in Life Science logistics while adding key Life Science specialty services for their programs in the Asia Pacific and Middle East regions. In recent presentation to Marken employees, Gerard Barba, CEO of Marken announced “ The opening of our directly owned depot in Singapore sets the corner stone of an expanding global network of GMP compliant distribution centers for Marken. “
The new 14,500 sq. ft. Clinical Trial Supply Depot offers the full range of secured storage conditions including
Clinical Trial Logistics services offered:
The expanded Marken office in Singapore provides Life Science material logistics and Clinical Trial Supply management for Pharmaceutical and Biotech customers throughout the Asia Pacific region. This represents Marken's latest investment in the region, which in 2010 saw the opening of a new office in Tokyo.s
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.